In this Issue
Increase in soluble protein oligomers triggers the innate immune system promoting inflammation and vascular dysfunction in the pathogenesis of sepsis
Clinical Science (18 July 2018) 132 (13): 1433–1438.
Clinical Science (18 July 2018) 132 (13): 1403–1415.
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction
Ping Chen; Jian-Nong Wu; Yang Shu; He-Guo Jiang; Xiao-Hui Zhao; Hai Qian; Kang Chen; Ting Lan; Chen-Guo Chen; Jian Li
Clinical Science (18 July 2018) 132 (13): 1417–1433.
Impact of PEGylation on the mucolytic activity of recombinant human deoxyribonuclease I in cystic fibrosis sputum
Marie-Julie Guichard; David Kinoo; Anne-Sophie Aubriot; Nathalie Bauwens; Jordane Gougué; François Vermeulen; Patrick Lebecque; Teresinha Leal; Rita Vanbever
Clinical Science (18 July 2018) 132 (13): 1439–1452.
Naomi C. Boisvert; Chet E. Holterman; Jean-François Thibodeau; Rania Nasrallah; Eldjonai Kamto; Cesar H. Comin; Luciano da F. Costa; Anthony Carter; Richard L. Hébert; Alex Gutsol; Gregory O. Cron; Baptiste Lacoste; Douglas A. Gray; Chris R. Kennedy
Clinical Science (18 July 2018) 132 (13): 1453–1470.
Galectin-3 down-regulates antioxidant peroxiredoxin-4 in human cardiac fibroblasts: a new pathway to induce cardiac damage
Jaime Ibarrola; Vanessa Arrieta; Rafael Sádaba; Ernesto Martinez-Martinez; Amaia Garcia-Peña; Virginia Alvarez; Amaya Fernández-Celis; Alicia Gainza; Enrique Santamaría; Joaquin Fernández-Irigoyen; Victoria Cachofeiro; Guillermo Zalba; Renaud Fay; Patrick Rossignol; Natalia López-Andrés
Clinical Science (18 July 2018) 132 (13): 1471–1485.
Cover ImageThe 3D structure of recombinant human deoxyribonuclease I. The N-terminal leucine shown in yellow at the top of the structure was selected for PEGylation of the protein. The amino acids shown in yellow towards the bottom of the protein are those interacting with globular actin, a potent inhibitor of human deoxyribonuclease I; for details, see pages 1439–1452.